BV联合AVD方案治疗新诊断早期预后不良霍奇金淋巴瘤
这项多中心四序贯队列研究纳入117例新诊断早期预后不良霍奇金淋巴瘤患者,接受4周期BV+AVD化疗。PET-4阴性者按队列接受不同放疗策略。2年无进展生存率94%,总生存率99%,不良反应可耐受,支持在PET-4阴性患者中安全减少或免除巩固放疗。
要点
- BV+AVD四周期方案在早期预后不良霍奇金淋巴瘤中高效低毒。
- PET-4阴性患者可安全减少或免除巩固放疗。
- 周围神经病变发生率54%,但大部分可逆。
核心结论
- BV+AVD四周期方案对早期预后不良霍奇金淋巴瘤高效且耐受良好,包括大肿块病变。
- PET-4阴性患者中减少或免除巩固放疗得到疗效支持。
研究设计与样本
- 多中心四序贯队列研究,纳入117例新诊断早期预后不良霍奇金淋巴瘤患者。
- 所有患者接受4周期BV+AVD化疗;PET-4阴性者按队列接受30Gy或20Gy累及部位放疗、30Gy巩固体积放疗或不放疗。
主要发现
- 队列1-4的完全缓解率分别为93%、100%、93%和97%。
- 中位随访3.8年,2年无进展生存率和总生存率分别为94%和99%。
- 队列1-4的2年无进展生存率分别为93%、97%、90%和97%。
- 不良事件包括中性粒细胞减少(44%)、发热性中性粒细胞减少(8%)和周围神经病变(54%),后者大部分可逆。
临床怎么用
- BV+AVD四周期可作为早期预后不良霍奇金淋巴瘤的高效初始治疗方案。
- PET-4阴性患者可考虑减少或免除巩固放疗以降低长期毒性。
局限性
- 研究为四序贯队列设计,非随机对照,放疗策略的疗效比较需谨慎解读。
- 中位随访时间较短(队列1-4分别为5.9、4.5、2.5和2.2年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To improve curability and limit long-term adverse effects for newly diagnosed early-stage (ES), unfavorable-risk Hodgkin lymphoma. METHODS: In this multicenter study with four sequential cohorts, patients received four cycles of brentuximab vedotin (BV) and doxorubicin, vinblastine, and dacarbazine (AVD). If positron emission tomography (PET)-4-negative, patients received 30-Gy involved-site radiotherapy in cohort 1, 20-Gy involved-site radiotherapy in cohort 2, 30-Gy consolidation-volume radiotherapy in cohort 3, and no radiotherapy in cohort 4. Eligible patients had ES, unfavorable-risk disease. Bulk disease defined by Memorial Sloan Kettering criteria (> 7 cm in maximal transverse or coronal diameter on computed tomography) was not required for cohorts 1 and 2 but was for cohorts 3 and 4. The primary end point was to evaluate safety for cohort 1 and to evaluate complete response rate by PET for cohorts 2-4. RESULTS: Of the 117 patients enrolled, 116 completed chemotherapy, with the median age of 32 years: 50% men, 98% stage II, 86% Memorial Sloan Kettering-defined disease bulk, 27% traditional bulk (> 10 cm), 52% elevated erythrocyte sedimentation rate, 21% extranodal involvement, and 56% > 2 involved lymph node sites. The complete response rate in cohorts 1-4 was 93%, 100%, 93%, and 97%, respectively. With median follow-up of 3.8 years (5.9, 4.5, 2.5, and 2.2 years for cohorts 1-4), the overall 2-year progression-free and overall survival were 94% and 99%, respectively. In cohorts 1-4, the 2-year progression-free survival was 93%, 97%, 90%, and 97%, respectively. Adverse events included neutropenia (44%), febrile neutropenia (8%), and peripheral neuropathy (54%), which was largely reversible. CONCLUSION: BV + AVD × four cycles is a highly active and well-tolerated treatment program for ES, unfavorable-risk Hodgkin lymphoma, including bulky disease. The efficacy of BV + AVD supports the safe reduction or elimination of consolidative radiation among PET-4-negative patients.
引用
- Kumar A, Casulo C, Advani RH, et al. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021. PMID: 33909449. doi:10.1200/JCO.21.00108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。